Tactiva Therapeutics 

Garwood Medical Devices logo.

Tactiva is a development stage immuno-oncology company with a unique approach to adoptive T-cell therapy. Tactiva's dual enhanced adoptive cell therapy (DEACTâ„¢) platform, consists of engineered CD4/CD8 cells which generate a durable supply of CD4 cells with direct anti-tumor activity as well as sustained helper function to CD8 T cell derived TCR-transduced effector T cells.  Tactiva Therapeutics is working to develop the next generation of cancer immunotherapies by utilizing a new approach to cell therapy. This type of personalized cancer treatment enhances the patient's immune system ability to tackle the disease.

Tactiva Therapeutics has been a partner to the University at Buffalo’s since January 2017 when it colocated at the New York State Center of Excellence in Bioinformatics and Life Sciences on the Buffalo Niagara Medical Campus.

Through the partnership with the University at Buffalo, Tactiva Therapeutics has received funding support from the UB Center for Advanced Technology in Big Data and Health Sciences that enabled a collaboration with UB’s Genomics and Bioinformatics Core, infrastructure that was funded by BIG in support of Tactiva’s discovery efforts.

The partnership with BIG provides Tactiva Therapeutics with access to equipment for their preclinical development of Tactiva’s DEACTTM platform.